DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more


Nutrilib.com
A comprihensive source of nutritional information

Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase

Information source: Protalix
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Gaucher Disease

Intervention: plant expressed recombinant human glucocerebrosidase (Drug)

Phase: Phase 3

Status: Not yet recruiting

Sponsored by: Protalix

Official(s) and/or principal investigator(s):
Ari Zimran, MD, Principal Investigator, Affiliation: Shaare Zedek Medical Center, Jerusalem

Overall contact:
Raul Chertkoff, MD, Phone: +972-4-9889488, Email: raul@protalix.com

Summary

This is a multi-center, open-label, switchover trial to assess the safety of prGCD in 15 patients with Gaucher disease who are currently being treated with imiglucerase (Cerezyme®) ERT. Eligible patients will enter a 12-week Stability Evaluation Period to establish the stability of their disease. Patients with stable disease will then be switched from their imiglucerase treatment to receive intravenous (IV) infusions of prGCD every two weeks for a total of 20 IV infusions. The dose of prGCD will be equal to each patient's previous imiglucerase dose. The infusions will be administered at the selected investigational site (clinic/hospital) At the end of the 9-month treatment period (20 visits, 38 weeks) eligible patients will be offered enrollment in an open-label extension study.

Clinical Details

Official title: A Phase 3 Multicenter, Open-Label, Switchover Trial to Assess the Safety and Efficacy of Plant Cell Expressed Recombinant Human Glucocerebrosidase in Patients With Gaucher Disease Treated With Imiglucerase

Study design: Treatment, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

Primary outcome: Adverse events

Secondary outcome: Platelet count

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Males and females, 18 years or older

- Female patients of child-bearing potential and male patients with female partners of

child-bearing potential must agree to use a medically acceptable method of contraception, not including the rhythm method

- Confirmed diagnosis of Gaucher disease by the enzymatic activity assay

- Stable Gaucher disease

- Treatment with imiglucerase (Cerezyme®) for at least 2 years and on a stable

maintenance regimen (dose unchanged) for at least the last six months

- Able to provide written informed consent

Exclusion Criteria:

- Currently taking another experimental drug for any condition

- Pregnant or nursing or planning to become pregnant

- History of allergy to carrots

- Presence of anti-glucocerebrosidase (GCD) antibodies

- Previous infusion reaction suspected to be allergic in nature to Cerezyme® or

Ceredase® or receiving premedication to prevent infusion reactions

- Presence of HIV and/or HBsAg and/or hepatitis C infection

- Presence of unresolved anemia due to iron, folic acid or vitamin B12 deficiency

- Presence of any significant comorbidity that could confound the interpretation of the

clinical response to prGCD

- Presence of any medical, emotional, behavioral or psychological condition that in the

judgment of the Investigator would interfere with the patient's compliance with the requirements of the study

Locations and Contacts

Raul Chertkoff, MD, Phone: +972-4-9889488, Email: raul@protalix.com

Shaare Zedek Medical Center, Jerusalem, Israel
Additional Information

Starting date: August 2008
Ending date: November 2009
Last updated: July 9, 2008

Page last updated: November 03, 2008

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008